Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Gothenburg, March 6, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company's commercially available iTANK platform, today provides an update on the ongoing Phase I/IIa CARMA study evaluating its lead CAR T-cell therapy candidate ELC-301 in patients with relapsed or refractory B-cell lymphoma. New data shows complete metabolic responses from the first two patients treated in cohort 3 (the highest dose level to date), as well as follow-up data from patients in cohorts 1 and 2. These results will be presented by the Company's Chief Scientific Officer, Professor Magnus Essand, during an invited scientific presentation today at the 10th Zurich Immuno-Oncology Conference 2026 in Zürich, Switzerland.
The CARMA study is a Phase I/IIa clinical trial assessing the safety, optimal dosing, and preliminary efficacy of ELC-301 in patients with relapsed or refractory B-cell lymphoma. It includes a dose-escalation phase (Phase I) across three cohorts to identify the maximum tolerated dose, followed by further evaluation in an expansion phase (Phase IIa).
Key highlights from the data:
- Both patients so far treated in cohort 3 achieved a complete metabolic response (CMR), meaning no detectable active disease/patients were disease-free - at the one-month follow-up assessment.
- No dose-limiting toxicities (DLTs) were observed, and the treatment was well tolerated across cohorts.
- Across the 8 patients treated to date:
- Disease control rate: 100%.
- Overall response rate (ORR): 7/8.
- CMR at month 1: 6/8.
- Of the 6 patients with confirmed CMR at month 1, 4 had sustained CMR at their last recorded follow-up.
- The best responses have so far been confirmed lasting up to at least 12 months.
The early positive signals from the highest dose cohort adds to the previous updates showing CMR in four of six patients in the first two cohorts (lower dose levels), with a favorable safety profile and no DLTs observed to date. The CARMA study continues to progress as planned, recruitment now ongoing in cohort 3 (targeting six patients total). ELC-301 is an iTANK-armed CAR T-cell therapy designed to target the CD20 antigen on B-cells while leveraging the proprietary iTANK platform to stimulate a broader, parallel immune response against cancer cells.
Magnus Essand, CSO of Elicera Therapeutics, commented:
"The one-month data from the first two patients in the highest dose group cohort 3, showing complete metabolic response without any dose-limiting toxicities, represent another important step forward for ELC-301 and our iTANK platform. These results reinforce the potential of iTANK-armed CAR T-cells to deliver deep and durable responses in heavily pretreated B-cell lymphoma patients. We are excited to share the full update, including extended follow-up from earlier cohorts, at the Zurich Immuno-Oncology Conference and remain committed to advancing this promising therapy toward further clinical development."
This information is such information as Elicera Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on March 3, 2026.